Pluvicto
Pluvicto
What is Pluvico?
Pluvicto(r) is a very high-tech and targeted medications that is used to
treat men with advanced prostate cancer. Pluvicto has been shown to help
men with advanced prostate cancer feel better and live longer. Our medical
practice is among the first in the regional to start treating with Pluvicto
and we have quite a bit of experience with taking care of men who have
advanced prostate cancer.
To schedule an initial consultation to see if you are a good candidate for Pluvicto, you or your cancer doctor can call our team at 504-503-5139 and press option 2 to schedule.
Which men benefit from Pluvicto?
Pluvicto has shown positive effects on men with metastatic castrate-resistant
prostate cancer. These are men whose prostate cancer has spread from the
prostate usually into lymph nodes and the bone, and sometimes into other
organs. Castrate-resistant refers to men who are no longer responding
well to anti-androgen medications including Lupron, Eligard, abiraterone,
or enzalutamide.
What do you need to know about Pluvicto therapy?
Pluvicto is most often given once every six weeks for six cycles in total.
Our physicians take less than five minutes to administer the drug, and
our patients are often headed back home within one hour of arriving. This
schedule is very patient-friendly – this schedule makes it easier
to treat patients from Alabama, Louisiana, Mississippi, and beyond, as
the disruption on your life and visits to our Center are fairly limited.
We are happy to work closely with your local doctors and treatment team.
Patients will continue with their treatment team after Pluvicto is complete.
How does it work?
Pluvicto contains both a radiotracer known as anti-PSMA, which selective
binds to prostate cancer cells, and also a payload of a radioactive particle
known as Lutetium-177. This allows Pluvicto to be specific and selective,
focusing on prostate cancer cells while causing much less damage to non-target
healthy tissues.
It is important to understand that we will ask you to do your part to help protection the general population from getting radiation exposure from this drug.
Case Study
This is a man in his early-80s-year-old man who was referred to us for
advanced prostate cancer who to us with disease in the bones and liver
and an PSA of 24.
Before: Figure 1 shows multiple areas of PSMA-uptake (the dark areas) which shows
prostate cancer in the bones and and liver nodes. This was performed about
one month before starting Pluvicto.
After: Figure 2 shows that all the areas of PSMA-uptake have resolved about
two months after his sixth and final dose of Pluvicto. His PSA has decreased
to non-detectable (<0.04). Almost two years later, his PSA remains
low at about 1.0.
Given his decline in early PSA along with his post-treatment imaging showing
an excellent response of all disease and no new disease, treating him
with Pluvicto should substantially prolonged survival.
Please note that this one specific patient example and that results vary; your result may be different.
Ask us a question
You are welcome to send ask us a question. While please understand –
the quickest and most direct way to get started on treatment would be
to come in for Consultation – sometime patients and their families
want to reach out to us first.
If you have symptoms of an urgent nature, please call your doctors or go to the emergency room immediately.
By submitting this form, you acknowledge the risk of sending this information electronically and via email and agree not to hold LCMC or Tulane University Medical Center liable for any damages you may incur as the result of the transfer or use of the information. More information regarding the confidentiality of this request can be found in our Privacy Policy. The use or transmittal of this form and any replies via email or phone does not create a physician-contact relationship.
For more information about treatment, fill out the information form here, and someone from our office will respond shortly.
